Clinical Scorecard: Monthly fasting cycles may be feasible in T2D
At a Glance
Category
Detail
Condition
Type 2 diabetes (T2D)
Key Mechanisms
Monthly 5-day fasting-mimicking diet (FMD) cycles; serum ketone levels were higher in the FMD group than in the usual-care group.
Target Population
Adults with T2D receiving metformin or no glucose-lowering medication.
Care Setting
Primary care; the study evaluated feasibility of adding monthly FMD cycles to usual care.
Key Highlights
In a 1-year randomized study of 100 participants, 61% assigned to monthly FMD cycles completed the program.
Among FMD participants, 31% discontinued because of diet-related issues and 8% for other reasons.
Treatment satisfaction did not differ between the FMD and usual-care groups.
Focus groups with 20 participants identified convenience, short cycles, not feeling hungry, internal motivation, belief in beneficial effects, perceived health improvements, and social support as adherence facilitators.
Taste, quantity, and frequency of the diet, environmental temptations, and lack of social support were reported as adherence barriers.
Guideline-Based Recommendations
Diagnosis
Management
The study evaluated monthly 5-day FMD cycles alongside usual care; it assessed feasibility, not long-term clinical effectiveness.
Study authors stated that addressing identified facilitators and barriers might enhance adherence.
Monitoring & Follow-up
The feasibility evaluation included program completion, reasons for discontinuation, serum ketone levels, and treatment satisfaction.
Risks
Diet-related difficulties contributed to discontinuation; 39% of participants assigned to FMD did not complete the 1-year program.
The findings may not apply to patients receiving glucose-lowering therapies other than metformin because those patients were not included.
Patient & Prescribing Data
100 participants with T2D were randomized: 51 to monthly 5-day FMD cycles plus usual care and 49 to usual care alone. Eligible participants were receiving metformin or no glucose-lowering medication.
The FMD program lasted 1 year. In the FMD group, 61% completed it; 31% discontinued because of diet-related issues and 8% for other reasons. Treatment satisfaction did not differ between groups.
Clinical Best Practices
Consider the study's limited sample size and restricted treatment population when interpreting its findings.
Account for reported dietary barriers, including taste, quantity, frequency, environmental temptations, and limited social support.
Recognize that the study assessed feasibility and did not establish long-term clinical effectiveness.
A splinter injury progressed to finger necrosis in a patient with MDS, despite antibacterial treatment and no clinically apparent systemic dissemination.
A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.
Single-nucleus sequencing of menstrual fluid identified epithelial gene signatures and prioritized five candidate biomarkers that warrant validation in larger studies.
